[Assessment of the use of a multicomponent drug in the treatment of new cases of pulmonary tuberculosis].
The multicomponent drug Mairin-P that contains isoniazid, 60 mg, rifampicin, 120 mg, pyrazinamide, 300 mg, and ethambutol hydrochloride, 225 mg, has been pharmacokinetically and clinically studied. There was no significant difference in the pharmacokinetic parameters of rifampicin as a component of Mairin-P and in combination with antitubercuous agents as free dosage forms. Treatment of first detected patients with pulmonary tuberculosis who isolate drug-sensitive Mycobacterium tuberculosis with Mairin-P is as effective as conventional treatment regimens with antituberculous drugs. Adverse reactions, including non-correctable one, due to the use of Mairin-P occur less frequently than to that of antituberculous drugs.
Semenova
O V
OV
D000293:Adolescent; D000328:Adult; D004338:Drug Combinations; D004977:Ethambutol / Q000008:administration & dosage / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D007538:Isoniazid / Q000008:administration & dosage / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D009169:Mycobacterium tuberculosis / Q000187:drug effects / Q000302:isolation & purification; D011718:Pyrazinamide / Q000008:administration & dosage / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D011859:Radiography; D012293:Rifampin / Q000008:administration & dosage / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D013183:Sputum / Q000382:microbiology; D013997:Time Factors; D014397:Tuberculosis, Pulmonary / Q000175:diagnosis / Q000000981:diagnostic imaging / Q000188:drug therapy*
D004338:Drug Combinations; C469386:Myrin P; D011718:Pyrazinamide; D004977:Ethambutol; D007538:Isoniazid; D012293:Rifampin